1 / 18

Precision Medicine: From stratified therapies to personalized therapies

Precision Medicine: From stratified therapies to personalized therapies. Fabrice ANDRE Institut Gustave Roussy Villejuif, France. Frequent cancers include high number of very rare genomic segments. (whole genome sequencing breast cancers). Stephens, Nature, 2012. Working hypothesis.

kaoru
Download Presentation

Precision Medicine: From stratified therapies to personalized therapies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Precision Medicine:From stratified therapies to personalized therapies Fabrice ANDRE Institut Gustave Roussy Villejuif, France

  2. Frequent cancers include high number of very rare genomic segments (whole genome sequencing breast cancers) Stephens, Nature, 2012

  3. Working hypothesis • Targeting mechanisms that lead to cancer progression can improve patient’s outcome • These mechanisms are individual • Goal: to identify the mechanism of cancer progression at the individual level, in order to target it

  4. Precision Medicine Concept: Identify the targets to be treated in each patient Clinical evidence What is the optimal Biotechnology ? Therapy matched to genomic alteration Molecular analysis What is the optimal Algorithm ? Target identification Andre, ESMO, 2012

  5. Outline • Stratified medicine • Personalized medicine

  6. Stratified medicine • Drug development or implementation in a strate defined by a molecular alteration FGFR1 amplification: 10% of breast cancer

  7. Translational research to feed stratified medicine FGFR1: amplification in 10% BC FGFR1 inhibitors present higher sensitivity on FGFR1-amplified CC Set-up genomic test (FISH) Run phase II trial Testing the FGFR1 Inh in patients with FGFR1 amp BC

  8. Research and medical questions related to stratified medicine • How to facilitate translation of discoveries ? • Develop translational research units • How to set-up a molecular assay for stratified medicine ? • Develop genomic units for clinical use • How to optimally run trials of stratified medicine ? • Set-up molecular screening programs

  9. Molecular screening programs: to identify patients eligible for phase I/II trials Trial A Molecular screening with High Throughput Genomics Trial B Target identification Trial C IF Progressive disease Trial D Trial E Trial F Andre, Delaloge, Soria, J Clin Oncol, 2011

  10. Ongoing molecular screening or personalized medicine programs in France Sponsor Pilot study 1st generation trials No NGS NGS Randomized trials Unified Database: Pick-up the winner targets SAFIR02 breast SAFIR01 Unicancer SAFIR02 lung preSAFIR (Arnedos, EJC, 2012) WINTHER Gustave Roussy MOSCATO (Hollebecque, ASCO 2013) Profiler MOST L Berard Lyon 2nd generation Algorithm for Personnalized medicine SHIVA (Letourneau AACR 2013) Curie Institute Overall : >2 000 planned patients (all tumor types), >800 already included Breast Cancer: > 1 000 planned, >70 already treated Goal: To generate optimal algorithm for individualized therapy

  11. Molecular screening: Challenges • No research in stratified medicine without molecular screening programs

  12. Evolution:GENOMIC DISEASES ARE BECOMING TO RARE OR COMPLEX TO ALLOW DRUG DEVELOPMENT IN GENOMIC SEGMENTS Are we going to make a drug development for this AKT1 mut / FGFR1 amp segment ? How to move forward ? Stephens, Nature, 2012

  13. Solution to improve outcome with targeted therapies in the genomic era: test the algorithm not the drug How to move there ???

  14. SAFIR02: Study Design 10 Targeted therapy According to 51 Molecular alterations Biopsy metastatic site: Next generation sequencing Array CGH R SOC Target defined by 1st generation Virtual cell (CCLE) Her2-negative metastatic breast cancer no more than 1 line chemotherapy Chemotherapy 6-8 cycles No PD metastatic NSCLC no more than 1 line chemotherapy EGFRwt / ALKwt No alteration Followed up but not included

  15. Ongoing molecular screening or personalized medicine programs in France Sponsor Pilot study 1st generation trials No NGS NGS Randomized trials Unified Database: Pick-up the winner targets SAFIR02 breast SAFIR01 Unicancer SAFIR02 lung preSAFIR (Arnedos, EJC, 2012) WINTHER Gustave Roussy MOSCATO (Hollebecque, ASCO 2013) Profiler MOST L Berard Lyon 2nd generation Algorithm for Personnalized medicine SHIVA (Letourneau AACR 2013) Curie Institute Overall : >2 000 planned patients (all tumor types), >800 already included Breast Cancer: > 1 000 planned, >70 already treated Goal: To generate optimal algorithm for individualized therapy

  16. Long term perspective 2018-2020 2013 2015 1st generation trials database 2nd generation algorithm 2nd generation trials database Targeting oncogenic drivers Integration of other systems: DNA repair Immunology metabolism

  17. Challenges / Research questions • Bioinformatic algorithm for treatment decision, that integrates all biological systems • Technologies: • whole exome sequencing • RNA seq • Protein-based assays

  18. Conclusion: genomic medicine for cancer patients • bioinformatic algorithm for treatment decision • Integration of DNA repair, immunology, metabolism in personalized medicine • large scale screening and implementation new technologies • Target identification for stratified medicine • understanding mechanisms of resistance

More Related